Research Spotlight

Posted March 15th 2018

Does the surgical approach for treating mandibular condylar fractures affect the rate of seventh cranial nerve injuries? A systematic review and meta-analysis based on a new classification for surgical approaches.

Larry M. Wolford D.M.D.

Larry M. Wolford D.M.D.

Al-Moraissi, E. A., A. Louvrier, G. Colletti, L. M. Wolford, F. Biglioli, M. Ragaey, C. Meyer and E. Ellis, 3rd (2018). “Does the surgical approach for treating mandibular condylar fractures affect the rate of seventh cranial nerve injuries? A systematic review and meta-analysis based on a new classification for surgical approaches.” J Craniomaxillofac Surg 46(3): 398-412.

Full text of this article.

PURPOSE: The purpose of this study was to determine the rate of facial nerve injury (FNI) when performing (ORIF) of mandibular condylar fractures by different surgical approaches. MATERIALS AND METHODS: A systematic review and meta-analysis were performed that included several databases with specific keywords, a reference search, and a manual search for suitable articles. The inclusion criteria were all clinical trials, with the aim of assessing the rate of facial nerve injuries when (ORIF) of mandibular condylar fractures was performed using different surgical approaches. The main outcome variable was transient facial nerve injury (TFNI) and permanent facial nerve injury (PFNI) according to the fracture levels, namely: condylar head fractures (CHFs), condylar neck fractures (CNFs), and condylar base fractures (CBFs). For studies where there was no delineation between CNFs and CBFs, the fractures were defined as CNFs/CBFs. The dependent variables were the surgical approaches. RESULTS: A total of 3873 patients enrolled in 96 studies were included in this analysis. TFNI rates reported in the literature were as follows: A) For the transoral approach: a) for strictly intraoral 0.72% (1.3 in CNFs and 0% for CBFs); b) for the transbuccal trocar instrumentation 2.7% (4.2% in CNFs and 0% for CBFs); and c) for endoscopically assisted ORIF 4.2% (5% in CNFs, and 4% in CBFs). B) For low submandibular approach 15.3% (26.1% for CNFs, 11.8% for CBFs, and 13.7% for CNFs/CBFs). C) For the high submandibular/angular subparotid approach with masseter transection 0% in CBFs. D) For the high submandibular/angular transmassetric anteroparotid approach 0% (CNFs and CBFs). E) For the transparotid retromandibular approach a) with nerve facial preparation 14.4% (23.9% in CNFs, 11.8% in CBFs and 13.7% for CNFs/CBFs); b) without facial nerve preparation 19% (24.3% for CNFs and 10.5% for CBFs). F) For retromandibular transmassetric anteroparotid approach 3.4% in CNFs/CBFs. G) For retromandibular transmassetric anteroparotid approach with preauricular extension 2.3% for CNFs/CBFs. H) For preauricular approach a) deep subfascial dissection plane 0% in CHFs b) for subfascial approach using traditional preauricular incision 10% (8.5% in CHFs and 11.5% in CNFs). I) For retroauricular approach 3% for CHFs. PFNI rates reported in the literature were as follows: A) for low submandibular approach 2.2%, B) for retromandibular transparotid approach 1.4%; C) for preauricular approach 0.33%; D) for high submandibular approach 0.3%; E) for deep retroparotid approach 1.5%. CONCLUSION: According to published data for CHFs, a retroauricular approach or deep subfascial preauricular approach was the safest to protect the facial nerve. For CNFs, a transmassetric anteroparotid approach with retromandibular and preauricular extension was the safest approach to decrease risk of FNI. For CBFs, high submandibular incisions with either transmassetric anteroparotid approach with retromandibular or transmassetric subparotid approach, followed by intraoral (with or without endoscopic/transbuccal trocar) were the safest approaches with respect to decreased risk of FNI.


Posted March 15th 2018

Asymptomatic Ascending Aorta Aneurysm With Severe Aortic Regurgitation Caused by Multiple Intimal-Medial Tears Unassociated With Aortic Dissection.

William C. Roberts M.D.

William C. Roberts M.D.

Velasco, C. E., H. Hashemi, C. P. Roullard, J. Machannaford and W. C. Roberts (2018). “Asymptomatic Ascending Aorta Aneurysm With Severe Aortic Regurgitation Caused by Multiple Intimal-Medial Tears Unassociated With Aortic Dissection.” Am J Cardiol 121(5): 668-669.

Full text of this article.

A 62-year-old man was found to have an asymptomatic ascending aortic aneurysm (6.6 cm) associated with severe aortic regurgitation. Operative resection of the wall of the aneurysm disclosed its cause to be multiple healed intimal-medial tears without dissection involving a previously normal aorta. The concept of an intimal-medial tear unassociated with aortic dissection is a poorly recognized entity and these tears appear to be asymptomatic and after the aortic tearing lead to aneurysmal formation.


Posted March 15th 2018

Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.

Milton Packer M.D.

Milton Packer M.D.

Vaduganathan, M., B. Claggett, M. Packer, J. J. V. McMurray, J. L. Rouleau, M. R. Zile, K. Swedberg and S. D. Solomon (2018). “Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.” JACC Heart Fail. Mar 4. [Epub ahead of print].

Full text of this article.

BACKGROUND: The lack of reliable predictors of the efficacy of drugs and devices in heart failure (HF) has presented a major hurdle to the development and evaluation of novel therapies. OBJECTIVES: To determine whether treatment-related changes in natriuretic peptides (NP) predict longer-term therapeutic effects in clinical trials of HF. METHODS: We conducted a trial-level analysis of 16 phase-3 chronic HF trials completed between 1987 and 2013 studying 18 therapeutic comparisons in 48,844 patients. We calculated weighted Pearson correlation coefficients between average control- or placebo-corrected changes in NPs and the longer-term treatment effects on clinical endpoints (expressed as log-transformed hazard ratios). RESULTS: Median follow-up for clinical endpoints was 28 (interquartile range: 18 to 36) months. NPs were available in a median of 748 (interquartile range: 270 to 1868) patients and measured at a median of 4 (interquartile range 3 to 6) months after randomization. Treatment-related changes in NPs were not correlated with longer-term treatment effects on all-cause mortality (r=0.12, P=0.63), but were correlated with HF hospitalization (r=0.63, P=0.008). Correlation with HF hospitalization improved when analyses were restricted to trials completed in the last decade (>2010; r=0.92, P=0.0095), employing NT-proBNP assays (r=0.65, P=0.06), and evaluating inhibitors of the renin-angiotensin-aldosterone-system (r=0.97, P=0.0002). CONCLUSIONS: When examining a broad range of interventions, therapy-related changes in NPs appeared modestly correlated with longer-term therapeutic effects on hospitalization for HF, but not with effects on all-cause mortality. These observations raise important caveats regarding the use of NPs in phase II trials for decision-making regarding phase III trials.


Posted March 15th 2018

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.

Harold M. Szerlip M.D.

Harold M. Szerlip M.D.

Tumlin, J. A., R. Murugan, A. M. Deane, M. Ostermann, L. W. Busse, K. R. Ham, K. Kashani, H. M. Szerlip, J. R. Prowle, A. Bihorac, K. W. Finkel, A. Zarbock, L. G. Forni, S. J. Lynch, J. Jensen, S. Kroll, L. S. Chawla, G. F. Tidmarsh and R. Bellomo (2018). “Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.” Crit Care Med. Mar 3. [Epub ahead of print].

Full text of this article.

OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy. DESIGN: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial. SETTING: ICUs. PATIENTS: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (n = 45 and n = 60, respectively). INTERVENTIONS: IV angiotensin II or placebo. MEASUREMENTS AND MAIN RESULTS: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of >/= 10 mm Hg or increase to >/= 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%-67%) and 30% (95% CI, 19%-41%) in patients treated with angiotensin II and placebo (p = 0.012), respectively. By day 7, 38% (95% CI, 25%-54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%-27%) placebo (p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%-68%) and 22% (95% CI, 12%-34%) of patients treated with angiotensin II and placebo (p = 0.001), respectively. CONCLUSIONS: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.


Posted March 15th 2018

The diminishing role of liver biopsy in live donor liver transplant.

James F. Trotter M.D.

James F. Trotter M.D.

Trotter, J. F. (2018). “The diminishing role of liver biopsy in live donor liver transplant.” Liver Transpl. Feb 21. [Epub ahead of print].

Full text of this article.

Persistent concerns about donor safety are reflected in the low level of activity in living donor liver transplantation (LDLT) in the United States, currently accounting for 4% of all liver transplants. One of the most important considerations in donor evaluation is the estimation of hepatic steatosis. In fact, most, but not all, centers disqualify live donor candidates with > 10% hepatic steatosis based primarily on donor safety as well as recipient outcomes. Donors with even mild hepatic steatosis (up to 10%) are more likely to have postoperative jaundice, which is evidence of impaired function of the remnant liver. While steatosis is associated with worse initial recipient graft function, the degree of steatosis placing the recipient at risk (> 0 %) is rarely a consideration for LDLT recipients. Hepatic steatosis is becoming more common due to the worldwide increase in obesity. Obesity is the most common indication to disqualify donor candidates early in the evaluation, in part, because of the increased likelihood of hepatitis steatosis as well as associated medical comorbidities. For remaining potential donors, accurate estimation of hepatic steatosis is critical. Fortunately, noninvasive imaging techniques (computed tomographic and magnetic resonance imaging [MRI]) have evolved since the introduction of LDLT more than 20 years ago. At that time, noninvasive imaging provided only a rough estimate of hepatic steatosis, which is insufficient to forego liver biopsy in many instances. Consequently, in this early era of LDLT, some centers elected to biopsy all donor candidates while other centers biopsied a smaller fraction. With more experience, it became apparent that protocol liver biopsy was not helpful in most cases and often identified trivial histologic abnormalities that created more confusion than clarity. Therefore, most centers (60%) follow a “reflexive” biopsy practice, i.e., liver biopsy is performed in selected candidates triggered by a specific abnormality, such as mild biochemical dysfunction or steatosis on magnetic resonance imaging (MRI). Recent advances have diminished reliance on liver biopsy in hepatology. These include ultrasound (US)-based and MRI-based hepatic elastography . For example, at our center, the number of liver biopsies has decreased 90 % in the past 10 years, due in large part to reliance on US-based elastography. Parenthetically, the decrease in performance of liver biopsies by hepatologists, even at busy centers, has resulted in trainees not acquiring sufficient experience in this procedure. Furthermore, advances in MRI techniques for estimating hepatic steatosis have become more sensitive and specific. In fact, the MR spectroscopy proton density fat fraction (MRS-PDFF) is accepted as a valid end point in clinical trials of new therapy for nonalcoholic fatty liver disease. (Excerpt from text, p. 1-3, advance text; no abstract available.)